Christopher S. Boerner, Ph.D., is the Chief Executive Officer of Bristol Myers Squibb, a leading global biopharmaceutical company. Dr. Boerner assumed the role of CEO in November 2020, bringing with him a wealth of experience in the biopharmaceutical industry. Prior to his appointment as CEO, he served as the company's Chief Commercialization Officer, where he was responsible for overseeing the commercialization of Bristol Myers Squibb's diverse portfolio of medicines across the globe. Dr. Boerner's professional journey in the biopharmaceutical sector spans over two decades. Before joining Bristol Myers Squibb, he held various leadership positions at companies such as Roche and Genentech, where he played a pivotal role in the development and commercialization of several blockbuster drugs. His expertise in strategic planning, business development, and product launches has been instrumental in driving growth and innovation at Bristol Myers Squibb. Under his leadership, the company has continued to expand its research and development efforts, focusing on groundbreaking treatments for cancer, cardiovascular diseases, and immunology. As CEO, Dr. Boerner is committed to advancing Bristol Myers Squibb's mission of discovering, developing, and delivering innovative medicines that transform patients' lives. He has been a strong advocate for fostering a culture of collaboration and excellence within the organization, emphasizing the importance of scientific innovation and patient-centric approaches. His strategic vision and leadership have positioned Bristol Myers Squibb as a frontrunner in the biopharmaceutical industry, with a robust pipeline of promising therapies and a dedication to improving global health outcomes.